• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Talphera Inc.

    10/28/25 4:28:15 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TLPH alert in real time by email
    S-8 1 acrx20251025_s8.htm FORM S-8 acrx20251025_s8.htm
     

    As filed with the Securities and Exchange Commission on October 28, 2025         

    Registration No. 333-

     


     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     


     

    FORM S-8

    REGISTRATION

    STATEMENT UNDER

    THE SECURITIES ACT OF 1933

     


     

    TALPHERA, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    41-2193603

    (State or other jurisdiction of Incorporation or organization)

    (I.R.S. Employer Identification No.)

     


     

    1850 Gateway Drive, Suite 175

    San Mateo, CA 94404

    (Address of principal executive offices) (Zip code)

     


     

    Amended and Restated 2020 Equity Incentive Plan

    Amended and Restated 2011 Employee Stock Purchase Plan

     

    (Full title of the plan)

     


     

    Raffi Asadorian

    Chief Financial Officer

    Talphera, Inc.

    1850 Gateway Drive, Suite 175

    San Mateo, CA 94404

    (650) 216-3500

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

     


     

    Copy to:

    John T. McKenna

    Cooley LLP

    3175 Hanover Street

    Palo Alto, California 94304

    (650) 843-5000

     


     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐

    Accelerated filer ☐

    Non-accelerated filer ☒ 

    Smaller reporting company ☒

    Emerging growth company ☐

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     

     

    EXPLANATORY NOTE

     

    Talphera, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 with the Securities and Exchange Commission (the “Commission”) for the purpose of registering 1,400,000 additional shares of common stock to be issued pursuant to the Registrant’s Amended and Restated 2020 Equity Incentive Plan (the “2020 Equity Incentive Plan”) and 100,000 additional shares of common stock to be issued pursuant to the Registrant’s Amended and Restated 2011 Employee Stock Purchase Plan (the “2011 Employee Stock Purchase Plan”). The contents of the Registrant’s registration statements on Form S-8 (SEC File Nos. 333-239213, 333-258896, 333-275720, and 333-281560 filed with the Commission on June 16, 2020, August 18, 2021 and November 22, 2023, and August 14, 2024, respectively) are incorporated by reference pursuant to General Instruction E of Form S-8.

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Information required by Part I of Form S-8 to be contained in the Section 10(a) prospectus is omitted from this Registration Statement in accordance with Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”). The document(s) containing the information specified in Part I will be sent or given to the participant in the 2020 Equity Incentive Plan and 2011 Employee Stock Purchase Plan pursuant to Rule 428(b)(1). These document(s) and the documents incorporated by reference in the Registration Statement pursuant to Item 3 of Part II of this form, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.         Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

     

     

    (a)

    the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 31, 2025; as amended by our Annual Report on Form 10-K/A for the year ended December 31, 2024, filed with the SEC on April 29, 2025 (the “2024 10-K”);

     

     

    (b)

    the Registrant’s Current Reports on Form 8-K, filed with the Commission on April 2, 2025, June 5, 2025, September 10, 2025; October 16, 2025; October 22, 2025; and October 24, 2025;

     

     

    (c)

    the Registrant’s Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2025 and June 30, 2025, filed with the Commission on May 14, 2025 and August 14, 2025, respectively; and

     

     

    (d)

    the description of the Registrant’s common stock which is contained in a registration statement on Form 8-A filed with the Commission on February 1, 2011 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as updated by Exhibit 4.1 of the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Commission on March 15, 2021, and any amendment or report filed for the purpose of updating such description.

     

     

     

     

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

    Item 4.         Exhibits.

     

           

    Incorporation by Reference

    Exhibit

    Number

     

    Exhibit Description

     

    Form

     

    SEC File No.

     

    Exhibit

     

    Filing Date

    3.1

     

    Amended and Restated Certificate of Incorporation of the Registrant.

     

    8-K

     

    001-35068

     

    3.1

     

    2/18/2011

    3.2

     

    Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant.

     

    8-K

     

    001-35068

     

    3.1

     

    6/25/2019

    3.3

     

    Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant.

     

    8-K

     

    001-35068

     

    3.1

     

    10/25/2022

    3.4

     

    Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant.

     

    8-K

     

    001-35068

     

    3.1

     

    1/9/2024

    3.5

     

    Amended and Restated Bylaws of the Registrant.

     

    8-K

     

    001-35068

     

    3.2

     

    1/9/2024

    4.1

     

    Reference is made to Exhibits 3.1 through 3.5.

                   

    4.2

     

    Specimen Common Stock Certificate of the Registrant.

     

    S-1/A

     

    333-170594

     

    4.2

     

    1/31/2011

    5.1*

     

    Opinion of Cooley LLP.

                   

    23.1*

     

    Consent of BPM LLP, Independent Registered Public Accounting Firm.

                   

    24.1

     

    Power of Attorney (included on the signature page of this Form S-8).

                   

    99.1+

     

    Amended and Restated 2020 Equity Incentive Plan.

     

    8-K

     

    001-35068

     

    10.1

     

    10/24/2025

    99.4+

     

    Amended and Restated 2011 Employee Stock Purchase Plan.

     

    8-K

     

    001-35068

     

    10.2

     

    10/24/2025

    107*

     

    Filing Fee Table

                   

     

     


     

    *

    Filed herewith.

    +

    Indicates management contract or compensatory plan.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S‑8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Mateo, State of California, on October 28, 2025.

     

     

    TALPHERA, INC.

     
           
     

    By:

    /s/ Vincent J. Angotti 

     
       

    Vincent J. Angotti

     
       

    Chief Executive Officer

     

     

    POWER OF ATTORNEY

     

    Know all persons by these presents, that each person whose signature appears below constitutes and appoints Vincent J. Angotti and Raffi Asadorian, and each or any one of them, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated. 

     

    Signature

     

    Title

     

    Date

             

    /s/ Vincent J. Angotti

     

    Chief Executive Officer and Director

     

    October 28, 2025

    Vincent J. Angotti

     

    (Principal Executive Officer)

       
             

    /s/ Raffi Asadorian

     

    Chief Financial Officer

     

    October 28, 2025

    Raffi Asadorian

     

    (Principal Financial and Accounting Officer)

       
             

    /s/ Adrian Adams

     

    Chairman

     

    October 28, 2025

    Adrian Adams

           
             

    /s/ Marina Bozilenko

     

    Director

     

    October 28, 2025

    Marina Bozilenko

           
             

    /s/ Jill Broadfoot

     

    Director

     

    October 28, 2025

    Jill Broadfoot

           
             

    /s/ Stephen J. Hoffman

     

    Director

     

    October 28, 2025

    Stephen J. Hoffman

           
             

    /s/ Abhinav Jain

     

    Director

     

    October 28, 2025

    Abhinav Jain

           
             

    /s/ Joseph Todisco

     

    Director

     

    October 28, 2025

    Joseph Todisco

           
             

    /s/ Mark Wan

     

    Director

     

    October 28, 2025

    Mark Wan

           

     

     
    Get the next $TLPH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TLPH

    DatePrice TargetRatingAnalyst
    1/28/2025$4.00Buy
    Rodman & Renshaw
    More analyst ratings

    $TLPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hoffman Stephen J was granted 4,267 shares, increasing direct ownership by 93% to 8,859 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    10/24/25 4:50:35 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wan Mark A was granted 4,267 shares, increasing direct ownership by 93% to 8,859 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    10/24/25 4:49:19 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bozilenko Marina was granted 4,267 shares, increasing direct ownership by 89% to 9,047 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    10/24/25 4:48:00 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Talphera with a new price target

    Rodman & Renshaw initiated coverage of Talphera with a rating of Buy and set a new price target of $4.00

    1/28/25 7:17:45 AM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025

    SAN MATEO, Calif., Nov. 5, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2025 financial results after market close on Wednesday, November 12, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast lin

    11/5/25 4:05:00 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera Announces the Appointment of Joe Todisco to Board of Directors

    SAN MATEO, Calif., Oct. 21, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Joe Todisco, the CEO of CorMedix Inc. (NASDAQ:CRMD) to its Board of Directors. In September 2025, CorMedix made a strategic investment in Talphera as part of the company's private placement financing. In connection with the closing of this transaction, CorMedix has the right to nominate a representative to the Talphera Board of Directors. The Company also provided CorMedix with a 60-day exclusive negotiation period follo

    10/21/25 8:30:00 AM ET
    $CRMD
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market

    CorMedix is making a strategic investment in Talphera as the lead investor, supported by existing stockholders Nantahala, Rosalind and Rock Springs with several new institutional investors $17 million in proceeds at first closing with the potential to receive an additional $12 million across one additional tranche upon the achievement of the primary endpoint in the NEPHRO clinical study The completion of this financing is expected to provide the company with sufficient capital through the planned approval of a Niyad PMA in the second half of 2026 SAN MATEO, Calif., Sept. 8, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), (Talphera), a specialty pharmaceutical company focused on the develo

    9/8/25 8:30:00 AM ET
    $CRMD
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Angotti Vincent J. bought $125,000 worth of shares (213,310 units at $0.59) and was granted 61,000 shares, increasing direct ownership by 149% to 474,769 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    4/3/25 4:28:23 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Aslam Shakil bought $6,038 worth of shares (5,695 units at $1.06), increasing direct ownership by 18% to 37,695 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    2/26/25 6:52:05 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Angotti Vincent J. bought $3,200 worth of shares (5,000 units at $0.64), increasing direct ownership by 2% to 208,066 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    12/6/24 6:05:05 AM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLPH
    SEC Filings

    View All

    SEC Form S-3 filed by Talphera Inc.

    S-3 - TALPHERA, INC. (0001427925) (Filer)

    10/28/25 4:29:06 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Talphera Inc.

    S-8 - TALPHERA, INC. (0001427925) (Filer)

    10/28/25 4:28:15 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - TALPHERA, INC. (0001427925) (Filer)

    10/24/25 4:30:22 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLPH
    Financials

    Live finance-specific insights

    View All

    Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025

    SAN MATEO, Calif., Nov. 5, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2025 financial results after market close on Wednesday, November 12, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast lin

    11/5/25 4:05:00 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update

    New sites accelerate registrational study enrollment - 15 patients have been enrolled in the NEPHRO study which remains on track with completion projected by the end of the year Cash and cash equivalents at June 30, 2025 were $6.8 million Conference call and webcast to be held Thursday, August 14, 2025 at 4:30 pm ET SAN MATEO, Calif., Aug. 14, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced second quarter 2025 financial results and provided a corporate update. "We have enrolled 15 patients in the NEPHRO clinical

    8/14/25 4:05:00 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025

    SAN MATEO, Calif., Aug. 7, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2025 financial results after market close on Thursday, August 14, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link

    8/7/25 4:35:00 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLPH
    Leadership Updates

    Live Leadership Updates

    View All

    Talphera Announces the Appointment of Joe Todisco to Board of Directors

    SAN MATEO, Calif., Oct. 21, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Joe Todisco, the CEO of CorMedix Inc. (NASDAQ:CRMD) to its Board of Directors. In September 2025, CorMedix made a strategic investment in Talphera as part of the company's private placement financing. In connection with the closing of this transaction, CorMedix has the right to nominate a representative to the Talphera Board of Directors. The Company also provided CorMedix with a 60-day exclusive negotiation period follo

    10/21/25 8:30:00 AM ET
    $CRMD
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

    ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive

    11/24/24 7:27:00 PM ET
    $LIAN
    $MGTX
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)